SAHPRA’s position on Semaglutide compounded products

News Healthcare & Pharma Statements & Speeches

Date: 13th Dec, 2023 Source: South African Health Products Regulatory Authority (SAHPRA) Country: South Africa Original Source

Brief

"On 13/12/2023", the "South African Health Products Regulatory Authority (SAHPRA)" issued an update regarding "SAHPRA’s position on Semaglutide compounded products". SAHPRA has registered Ozempic, a product containing semaglutide, for treating Type 2 Diabetes and reducing cardiovascular risk. However, the authority warns that compounded medicines claiming to contain semaglutide may not be safe or effective, emphasizing the importance of using SAHPRA-approved products.

This content is restricted.

Highlights content goes here...

This content is restricted.

South African Health Products Regulatory Authority (SAHPRA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

SAHPRA’s position on Semaglutide compounded products

Brief

South African Health Products Regulatory Authority (SAHPRA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

SAHPRA’s position on Semaglutide compounded products

Brief

South African Health Products Regulatory Authority (SAHPRA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.